{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:11:25Z","timestamp":1792681885092,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10096-024-04948-y","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T07:01:32Z","timestamp":1727766092000},"page":"2361-2369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical experience with ceftazidime\/avibactam for the treatment of extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in neonates and children"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2202-7645","authenticated-orcid":false,"given":"Ozlem Ozgur","family":"Gundeslioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-5137","authenticated-orcid":false,"given":"Zeliha","family":"Haytoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9071-9606","authenticated-orcid":false,"given":"Hatice Hale","family":"Gumus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6675-3150","authenticated-orcid":false,"given":"Faruk","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-2399","authenticated-orcid":false,"given":"Filiz","family":"Kibar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5803-878X","authenticated-orcid":false,"given":"Ummuhan","family":"Cay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4809-2883","authenticated-orcid":false,"given":"Derya","family":"Alabaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2092-8426","authenticated-orcid":false,"given":"Ferda","family":"Ozlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7590-650X","authenticated-orcid":false,"given":"Ozden Ozgur","family":"Horoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0739-5108","authenticated-orcid":false,"given":"R\u0131za Dincer","family":"Y\u0131ld\u0131zdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"4948_CR1","unstructured":"O\u2019Neill J (2016) Review on Antimicrobial Resistance. Tacling Drug-Resistant Infections Globally. Available from: https:\/\/amr-review.org\/sites\/default\/files\/160525_Final%20paper_with%20cover.pdf. Accessed 21 March 2024"},{"key":"4948_CR2","unstructured":"WHO (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. https:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1. Accessed 2 Apr 2024"},{"key":"4948_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/femsre\/fux013","volume":"41","author":"S Navon-Venezia","year":"2017","unstructured":"Navon-Venezia S, Kondratyeva K, Carattoli A (2017) Klebsiella pneumoniae: A major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev 41:252\u2013275","journal-title":"FEMS Microbiol Rev"},{"issue":"8","key":"4948_CR4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/INF.0000000000002344","volume":"38","author":"E Iosifidis","year":"2019","unstructured":"Iosifidis E, Chorafa E, Agakidou E, Kontou A, Violaki A, Volakli E et al (2019) Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children <5 Years of Age. Pediatr Infect Dis J 38(8):812\u2013815","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"4948_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/jpids\/piz085","volume":"9","author":"K Chiotos","year":"2020","unstructured":"Chiotos K, Hayes M, Gerber JS, Tamma PD (2020) Treatment of carbapenem-resistant enterobacteriaceae infections in children. J Pediatric Infect Dis Soc 9(1):56\u201366","journal-title":"J Pediatric Infect Dis Soc"},{"key":"4948_CR6","unstructured":"https:\/\/worldhealthorg.shinyapps.io\/WHO-AMR-Dashboard\/?_ga=2.172166563.1827800992.1668654440-1324205868.1668654440. Accessed 10 Feb 2024"},{"issue":"2","key":"4948_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5578\/flora.20239913","volume":"28","author":"HH G\u00fcm\u00fc\u015f","year":"2023","unstructured":"G\u00fcm\u00fc\u015f HH, K\u00f6ksal F (2023) Carbapenem-resistant Klebsiella pneumoniae: Resistance mechanisms, epidemiology, and mortality. Flora 28(2):131\u2013143","journal-title":"Flora"},{"issue":"6","key":"4948_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2165\/11318430-000000000-00000","volume":"70","author":"C Bebrone","year":"2010","unstructured":"Bebrone C, Lassaux P, Vercheval L, Sohier JS, Jehaes A, Sauvage E et al (2010) Current challenges in antimicrobial chemotherapy: focus on \u00df-lactamase inhibition. Drugs 70(6):651\u2013679","journal-title":"Drugs"},{"issue":"6","key":"4948_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M (2018) Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs 78(6):675\u2013692","journal-title":"Drugs"},{"key":"4948_CR10","unstructured":"European Medicines Agency (2016) European public assessment report: Zavicefta (ceftazidime\/avibactam). http:\/\/www.ema .europa.eu. Accessed 16 Mar 2024"},{"issue":"29","key":"4948_CR11","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","volume":"109","author":"DE Ehmann","year":"2012","unstructured":"Ehmann DE, Jahi\u0107 H, Ross PL, Gu RF, Hu J, Kern G et al (2012) Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor. Proc Natl Acad Sci U S A 109(29):11663\u201311668","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4948_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268\u2013281","journal-title":"Clin Microbiol Infect"},{"key":"4948_CR13","doi-asserted-by":"crossref","unstructured":"Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, et al. National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH\u2013ARORI). Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018;67(12):1803\u20131814.","DOI":"10.1093\/cid\/ciy378"},{"key":"4948_CR14","doi-asserted-by":"publisher","unstructured":"Currie\u00a0C J,\u00a0Berni\u00a0E,\u00a0Jenkins-Jones\u00a0S,\u00a0Poole\u00a0C D,\u00a0Ouwens\u00a0M,\u00a0Driessen\u00a0S\u00a0et al.\u00a0Antibiotic treatment failure in four common infections in UK primary care 1991\u20132012: longitudinal analysis\u00a0BMJ\u00a02014;\u00a0349\u00a0:g5493\u00a0https:\/\/doi.org\/10.1136\/bmj.g5493","DOI":"10.1136\/bmj.g5493"},{"key":"4948_CR15","doi-asserted-by":"publisher","unstructured":"Garcia LS, Isenberg HD (eds) (2010) Clinical microbiology procedures handbook, 3rd edn. ASM Press, Washington, DC. https:\/\/doi.org\/10.1128\/9781555817435","DOI":"10.1128\/9781555817435"},{"issue":"9","key":"4948_CR16","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/INF.0000000000002395","volume":"38","author":"JS Bradley","year":"2019","unstructured":"Bradley JS, Roilides E, Broadhurst H, Cheng K, Huang LM, MasCasullo V et al (2019) Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children \u22653 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized. Controlled Trial Pediatr Infect Dis J 38(9):920\u2013928","journal-title":"Controlled Trial Pediatr Infect Dis J"},{"issue":"8","key":"4948_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/INF.0000000000002392","volume":"38","author":"JS Bradley","year":"2019","unstructured":"Bradley JS, Broadhurst H, Cheng K, Mendez M, Newell P, Prchlik M et al (2019) Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children \u22653 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized. Controlled Trial Pediatr Infect Dis J 38(8):816\u2013824","journal-title":"Controlled Trial Pediatr Infect Dis J"},{"key":"4948_CR18","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.2147\/IDR.S426326","volume":"16","author":"H Meng","year":"2023","unstructured":"Meng H, Zhao Y, An Q, Zhu B, Cao Z, Lu J (2023) Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study. Infect Drug Resist 16:5815\u20135824","journal-title":"Infect Drug Resist"},{"issue":"1 Suppl 1","key":"4948_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2021-052888B","volume":"149","author":"MM Bembea","year":"2022","unstructured":"Bembea MM, Agus M, Akcan-Arikan A, Alexander P, Basu R, Bennett TD et al (2022) Pediatric Organ Dysfunction Information Update Mandate (PODIUM) Contemporary Organ Dysfunction Criteria: Executive Summary. Pediatrics 149(1 Suppl 1):1\u201312","journal-title":"Pediatrics"},{"key":"4948_CR20","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2024) Breakpoint tables for interpretation of MICs and zone diameters, version 14.0. Available at: http:\/\/www.eucast.org\/clinical_breakpoints\/"},{"issue":"10325","key":"4948_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399(10325):629\u2013655","journal-title":"Lancet"},{"key":"4948_CR22","unstructured":"World Health Organization (2014) Antimicrobial resistance: Global report on surveillance.\u00a0\u00a0https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/112642\/9789241564748_eng.pdf?sequence=1&isAllowed=y (Accessed on junel 3, 2024)."},{"key":"4948_CR23","unstructured":"World Health Organization. Guidelines for teh prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in health care facilities. file:\/\/\/C:\/Users\/khall\/Downloads\/9789241550178-eng.pdf. Accessed on July, 2024"},{"issue":"8","key":"4948_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1097\/INF.0000000000001188","volume":"35","author":"C Montagnani","year":"2016","unstructured":"Montagnani C, Prato M, Scolfaro C, Colombo S, Esposito S, Tagliabue C et al (2016) Carbapenem-resistant Enterobacteriaceae Infections in Children: An Italian Retrospective Multicenter Study. Pediatr Infect Dis J 35(8):862\u2013868","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"4948_CR25","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1097\/INF.0b013e3182804b49","volume":"32","author":"HC Maltezou","year":"2013","unstructured":"Maltezou HC, Kontopidou F, Katerelos P, Daikos G, Roilides E, Theodoridou M (2013) Infections caused by carbapenem-resistant Gram-negative pathogens in hospitalized children. Pediatr Infect Dis J 32(4):e151\u2013e154","journal-title":"Pediatr Infect Dis J"},{"key":"4948_CR26","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/cid\/cis543","volume":"55","author":"LK Logan","year":"2012","unstructured":"Logan LK (2012) Carbapenem-resistant enterobacteriaceae: an emerging problem in children. Clin Infect Dis 55:852\u2013859","journal-title":"Clin Infect Dis"},{"issue":"12","key":"4948_CR27","doi-asserted-by":"publisher","first-page":"e01440","DOI":"10.1128\/AAC.01440-17","volume":"61","author":"K Chiotos","year":"2017","unstructured":"Chiotos K, Tamma PD, Flett KB, Naumann M, Karandikar MV, Bilker WB et al (2017) Multicenter Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children. Antimicrob Agents Chemother 61(12):e01440-e1517","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4948_CR28","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/jac\/dkac083","volume":"77","author":"S Naha","year":"2022","unstructured":"Naha S, Sands K, Mukherjee S, Dutta S, Basu S (2022) A 12 year experience of colistin resistance in Klebsiella pneumoniae causing neonatal sepsis: two-component systems, efflux pumps, lipopolysaccharide modification and comparative phylogenomics. J Antimicrob Chemother 77(6):1586\u20131591","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4948_CR29","doi-asserted-by":"publisher","first-page":"E23","DOI":"10.1111\/1469-0691.12070","volume":"19","author":"A Capone","year":"2013","unstructured":"Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M et al (2013) High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 19(1):E23-30","journal-title":"Clin Microbiol Infect"},{"key":"4948_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.22159\/ajpcr.2017.v10i9.18369","volume":"10","author":"BH Bhaskari","year":"2017","unstructured":"Bhaskari BH, Mulki SS, Joshi S, Adhikari R, Venkateshi BM (2017) Col\u0131st\u0131n res\u0131stance \u0131n carbapenem-res\u0131stant klebs\u0131ella pneumon\u0131ae stra\u0131ns. Asian J Pharm Clin Res 10:70\u201373","journal-title":"Asian J Pharm Clin Res"},{"issue":"9","key":"4948_CR31","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1128\/JCM.00268-17","volume":"55","author":"KL Chew","year":"2017","unstructured":"Chew KL, La MV, Lin RTP, Teo JWP (2017) Colistin and polymyxin B susceptibility testing for carbapenem-resistant and mcr-positive enterobacteriaceae: comparison of sensititre, MicroScan, Vitek 2, and etest with broth microdilution. J Clin Microbiol 55(9):2609\u20132616","journal-title":"J Clin Microbiol"},{"issue":"9","key":"4948_CR32","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1093\/cid\/ciaa121","volume":"71","author":"MJ Satlin","year":"2020","unstructured":"Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G et al (2020) Clinical and laboratory standards institute and european committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis 71(9):e523\u2013e529","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4948_CR33","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","volume":"34","author":"D Yahav","year":"2020","unstructured":"Yahav D, Giske CG, Gr\u0101matniece A, Abodakpi H, Tam VH, Leibovici L (2020) New \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combinations. Clin Microbiol Rev 34(1):e00115-e120","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"4948_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cmi.2017.08.030","volume":"24","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Giacobbe DR, Giamarellou H, Viscoli C, Daikos GL, Dimopoulos G et al (2018) Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect 24(2):133\u2013144","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"4948_CR35","doi-asserted-by":"publisher","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV et al (2017) Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother 61(8):e00883-e917","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4948_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","volume":"66","author":"D van Duin","year":"2018","unstructured":"van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F et al (2018) Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Infect Dis 66(2):163\u2013171","journal-title":"Clin Infect Dis"},{"issue":"12","key":"4948_CR37","doi-asserted-by":"publisher","first-page":"ofz522","DOI":"10.1093\/ofid\/ofz522","volume":"6","author":"SCJ Jorgensen","year":"2019","unstructured":"Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM et al (2019) Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infect Dis. 6(12):ofz522","journal-title":"Open Forum Infect Dis."},{"issue":"3","key":"4948_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/ciy492","volume":"68","author":"M Tumbarello","year":"2019","unstructured":"Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C et al (2019) Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 68(3):355\u2013364","journal-title":"Clin Infect Dis."},{"issue":"3","key":"4948_CR39","doi-asserted-by":"publisher","first-page":"e02320","DOI":"10.1128\/AAC.02320-19","volume":"64","author":"V Tsolaki","year":"2020","unstructured":"Tsolaki V, Mantzarlis K, Mpakalis A, Malli E, Tsimpoukas F, Tsirogianni A et al (2020) Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients. Antimicrob Agents Chemother 64(3):e02320-e2419","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"4948_CR40","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/INF.0000000000002807","volume":"39","author":"Y Coskun","year":"2020","unstructured":"Coskun Y, Atici S (2020) Successful treatment of pandrug-resistant klebsiella pneumoniae infection with ceftazidime-avibactam in a preterm infant: a case report. Pediatr Infect Dis J 39(9):854\u2013856","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"4948_CR41","first-page":"192","volume":"27","author":"SS Asfour","year":"2022","unstructured":"Asfour SS, Alaklobi FA, Abdelrahim A, Taha MY, Asfour RS, Khalil TM et al (2022) Intravenous ceftazidime-avibactam in extremely premature neonates with carbapenem-resistant enterobacteriaceae: two case reports. J Pediatr Pharmacol Ther 27(2):192\u2013197","journal-title":"J Pediatr Pharmacol Ther"},{"key":"4948_CR42","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s10096-024","volume":"43","author":"A Guzek","year":"2024","unstructured":"Guzek A, Rybicki Z, Tomaszewski D et al (2024) Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime\/avibactam and aztreonam at a single center in Poland. Eur J Clin Microbiol Infect Dis 43:1579\u20131587. https:\/\/doi.org\/10.1007\/s10096-024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"4948_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo A et al (2022) European society of clinical microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect 28(4):521\u2013547","journal-title":"Clin Microbiol Infect"},{"key":"4948_CR44","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections. Infectious Diseases Society of America. Version 4.0. Availableat https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/. Accessed 26 Jul 2024","DOI":"10.1093\/cid\/ciae403"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04948-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-04948-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04948-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T04:04:20Z","timestamp":1732939460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-04948-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["4948"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-04948-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4605917\/v1","asserted-by":"object"}]},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study was obtained from the <i>Cukurova University Faculty of Medicine Ethics Committee<\/i> (05.04.2024\u2013143\/20). This study was conducted in compliance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines and local regulatory requirements. Due to the retrospective nature of the present research, no personal informed consent was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}